Dysbiosis Clinical Trial
Official title:
A Pilot Study to Assess the Intestinal MicroBiota Diversification States and Changes in U.S. Travelers After Return From Short-Term Travel to an Overseas South(East) Asian Destination
This prospective, observational pilot study is designed to assess feasibility, refine the
target population, and quickly test qualitative and quantitative changes in the microbiome
after short-term travel to South or Southeast Asia, regions where rates of travelers'
diarrhea and intestinal colonization with antimicrobial resistant bacteria are highest.
To measure the diversity change of the intestinal microbiota, participants will complete a
questionnaire and provide a stool specimen at three different time points: prior to
traveling, two weeks after returning from traveling, and 14 weeks after returning from
traveling.
Travelers' diarrhea is the most common illness experienced by those going overseas. Estimates
vary, but incidence has been reported to range between 30-60%, depending on travel
destination and season. Multiple organisms have been implicated as causes of travelers'
diarrhea, but bacteria account for 80-90% of cases. There is mounting evidence that the
integrity of the intestinal microbiome may be a strong modulator of diarrheal disease, and
that intestinal infections and other factors, including stress, antibiotic exposure, and diet
may disrupt the diversity and overall composition of the microbiome. Dysbiosis, a state of
altered microbiota diversity, may be less resistant to the acquisition of intestinal
pathogens and colonization of multiple drug resistant organisms. Furthermore, disruptions in
the microbiome that may result from an episode of travelers' diarrhea may have a role in the
development of chronic diarrhea and post-infectious irritable bowel syndrome.
This prospective, observational pilot study is intended to obtain preliminary data to support
the rationale for a subsequent larger cohort study. This study is designed to assess
feasibility, refine the target population, and quickly test qualitative and quantitative
changes in the microbiome after short-term travel (seven to 21 days) to South or Southeast
Asia, regions where rates of travelers' diarrhea and intestinal colonization with
antimicrobial resistant bacteria are highest.
The target population will include 10 Emory University students and/or Emory University
Hospital TravelWell Clinic (TWC) patients who have international travel plans. Consented,
willing, and eligible participants will complete an initial eligibility screening, followed
by pre-travel, short-term post-travel, and long-term post-travel study visits. To determine
specific factors associated with diversity change of the intestinal microbiota and changes in
the presence of genes that code for antibiotic resistance, questionnaires designed to collect
data on demographics, medical history, diet, food intake, recent (within 12 weeks of
pre-travel assessment, during travel, or post-travel) illness history, medication use, travel
itinerary, travel activities, and relevant food and water risk behaviors will be completed at
each study visit. A stool sample will also be provided at each time point. Participants may
also choose to take part in an optional sub-study which involves banking leftover stool for
future research use.
The primary protocol objective is to pilot a study investigating the association between
travel and changes in the intestinal microbiome (including both bacterial and fungal
components) and the bacterial and fungal resistome.
The secondary protocol objective is to assess microbiota profile changes and reversion to or
toward the pre-travel state by comparing pre-travel stool specimen sequencing results to
short-term post-travel and long-term post-travel stool specimen sequencing results.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05560087 -
Association of PeRiODontal Disease and gUt Microbiome With Coronary artEry Disease (PRODUCE Study)
|
||
Recruiting |
NCT05288790 -
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
|
Phase 2 | |
Completed |
NCT06423586 -
Effect of Lecithin-based Curcuma and Boswellia on Post-acute COVID-19 IBS
|
N/A | |
Completed |
NCT05575050 -
Impact of Teeth Brushing in Ventilated COVID-19 Patients.
|
N/A | |
Completed |
NCT04079218 -
Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial
|
Phase 4 | |
Active, not recruiting |
NCT03554278 -
Alteration of Stool Microbiota in Preterm Infants With Anemia
|
||
Completed |
NCT03659240 -
Prebiotic Effects of a Polyphenol-rich Food Product
|
N/A | |
Completed |
NCT04118049 -
Vaginal Probiotics and Pessaries and Their Impact on the Vaginal Microenvironment
|
N/A | |
Enrolling by invitation |
NCT06122636 -
Efficacy of a Probiotic and Microbiological Analysis on Oral Complications Induced by Antineoplastic Therapies in Patients With HNC
|
N/A | |
Recruiting |
NCT04200521 -
The Effect of Bariatric Procedures on Gut Microbiota in Obese Individuals in United Arab Emirates and Lebanon
|
||
Completed |
NCT03523403 -
Obesity-related Health Benefits of Apples
|
N/A | |
Recruiting |
NCT05176535 -
Determination of Vaginal Colonization and the Effect of an Oral Probiotic (PROSALVAG)
|
N/A | |
Recruiting |
NCT06005298 -
Alcohol Misuse, Gut Microbial Dysbiosis and PrEP Care Continuum: Application and Efficacy of SBIRT Intervention
|
N/A | |
Completed |
NCT03675048 -
Lactobacillus Reuteri DSM 17938 in Gut Microbiota Development in Infant Born by Caesarean Section
|
N/A | |
Recruiting |
NCT05790564 -
Almonds to Improve Gut Health and Decrease Inflammation
|
N/A | |
Completed |
NCT04561284 -
Carbohydrate-induced Resilience of the Gut Microbiome After Antibiotics Use
|
N/A | |
Enrolling by invitation |
NCT04527055 -
The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication
|
Phase 4 | |
Recruiting |
NCT05622721 -
REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs
|
||
Recruiting |
NCT05632497 -
Alteration of Symbiosis Intestinal Microbiota on Patients With Anorexia Nervosa
|
||
Recruiting |
NCT04790825 -
Periodontal Therapy on the Gut Microbiome of Inflammatory Bowel Disease
|
N/A |